Sutro Biopharma, Inc. (STRO)

Market Cap	491.90M +569.4%
Revenue (ttm)	99.61M +49.9%
Net Income	-153.60M
EPS	-15.87
Shares Out	16.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	321,528
Open	27.58
Previous Close	27.38
Day's Range	27.42 - 29.88
52-Week Range	6.74 - 43.85
Beta	1.64
Analysts	Strong Buy
Price Target	46.55 (+56.79%)
Earnings Date	May 14, 2026

About STRO

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: STRO
• Website: https://www.sutrobio.com

Financial Performance

In 2025, Sutro Biopharma's revenue was $102.48 million, an increase of 65.18% compared to the previous year's $62.04 million. Losses were -$191.09 million, -15.99% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price target is $46.55, which is an increase of 56.79% from the latest price.

Price Target

$46.55

(56.79% upside)

Analyst Consensus: Strong Buy